Physician profile
Anthony Pham
NPI 1790913994
$1,914.72
in general payments reported to CMS, 2019-2025
14 companies · $42.02 in 2025
The $42.02 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2021: $11.92 · 2022: $20.37 · 2024: $1,527 · 2025: $42.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,463 · Food and Beverage: $91.02 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,462.50 |
| Food and Beverage | $91.02 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,511.50 | 2024 | Brukinsa |
| Sirtex Medical INC | $188.93 | 2019 | |
| Biocompatibles, INC. | $114.17 | 2019 | |
| Astellas Pharma US INC | $42.02 | 2025 | Vyloy |
| Otsuka America Pharmaceutical, INC. | $20.37 | 2022 | |
| Aveo Pharmaceuticals, INC. | $15.00 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Merck Sharp & Dohme LLC | $10.81 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.